Myriad Genetics Inc
NASDAQ:MYGN

Watchlist Manager
Myriad Genetics Inc Logo
Myriad Genetics Inc
NASDAQ:MYGN
Watchlist
Price: 5.72 USD 3.06% Market Closed
Market Cap: 527.3m USD

Operating Margin
Myriad Genetics Inc

-15%
Current
-16%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-15%
=
Operating Profit
-124.5m
/
Revenue
831.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Myriad Genetics Inc
NASDAQ:MYGN
522.2m USD
-15%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.5B USD
30%
US
Amgen Inc
NASDAQ:AMGN
159.5B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
140.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.7B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
118B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.6B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.5B USD
-5%

Myriad Genetics Inc
Glance View

Market Cap
522.2m USD
Industry
Biotechnology

Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds. Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.

MYGN Intrinsic Value
18.96 USD
Undervaluation 70%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-15%
=
Operating Profit
-124.5m
/
Revenue
831.3m
What is the Operating Margin of Myriad Genetics Inc?

Based on Myriad Genetics Inc's most recent financial statements, the company has Operating Margin of -15%.

Back to Top